Evidence map›Paper›PMID 38483920›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Reactive Oxygen Species-Responsive Nanoparticles Toward Extracellular Matrix Normalization for Pancreatic Fibrosis Regression.

Liang Qi, Bo-Wen Duan, Hui Wang, Yan-Jun Liu, Han Han, Meng-Meng Han, Lei Xing, Hu-Lin Jiang, Stephen J Pandol, Ling Li

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Ferrum@albumin assembled nanoclusters inhibit NF-Acta pharmaceutica Sinica. B · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Liang QiDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Bo-Wen DuanState Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
Hui WangDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Yan-Jun LiuState Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
Han HanState Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
Meng-Meng HanState Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
Lei XingState Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
Hu-Lin JiangState Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.ORCID 0000-0002-1620-1777
Stephen J PandolDivision of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Ling LiDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
China Pharmaceutical University · CNZhongda Hospital Southeast University · CNCedars-Sinai Medical Center · US

Funding

Key Research & Development Program BE2022853Medical Key Discipline of Jiangsu Province ZDXK202203National Natural Science Foundation 81970717National Natural Science Foundation 82000740National Natural Science Foundation 82073398National Natural Science Foundation 82170845National Natural Science Foundation Major International (Regional) Joint Research Program 82020108029National Natural Science Foundation Major International (Regional) Joint Research Program 82320108003
6 · The paper itself

Abstract

Pancreatic fibrosis (PF) is primarily characterized by aberrant production and degradation modes of extracellular matrix (ECM) components, resulting from the activation of pancreatic stellate cells (PSCs) and the pathological cross-linking of ECM mediated by lysyl oxidase (LOX) family members. The excessively deposited ECM increases matrix stiffness, and the over-accumulated reactive oxygen species (ROS) induces oxidative stress, which further stimulates the continuous activation of PSCs and advancing PF; challenging the strategy toward normalizing ECM homeostasis for the regression of PF. Herein, ROS-responsive and Vitamin A (VA) decorated micelles (named LR-SSVA) to reverse the imbalanced ECM homeostasis for ameliorating PF are designed and synthesized. Specifically, LR-SSVA selectively targets PSCs via VA, thereby effectively delivering siLOXL1 and resveratrol (RES) into the pancreas. The ROS-responsive released RES inhibits the overproduction of ECM by eliminating ROS and inactivating PSCs, meanwhile, the decreased expression of LOXL1 ameliorates the cross-linked collagen for easier degradation by collagenase which jointly normalizes ECM homeostasis and alleviates PF. This research shows that LR-SSVA is a safe and efficient ROS-response and PSC-targeted drug-delivery system for ECM normalization, which will propose an innovative and ideal platform for the reversal of PF.

Indexed as

Extracellular MatrixFibrosisNanoparticlesReactive Oxygen SpeciesAnimalsDisease Models, AnimalDrug Delivery SystemsHumansMiceOxidative StressPancreasPancreatic DiseasesPancreatic Stellate CellsRatsResveratrolVitamin AReactive Oxygen SpeciesResveratrolVitamin Acollagen cross‐linkingextracellular matrixPancreatic fibrosispancreatic stellate cellsreactive oxygen species

Identifiers

PMID38483920
PMCPMC11109658
OpenAlexW4392797389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.